EURETINA 2020 Virtual - Programme Schedule

Programme ScheduleProgramme Overview
EURETINA Sessions Keynotes Symposia Instructional Courses Free Paper Abstracts Poster Abstracts Prize Papers All Days Fri 2nd Sat 3rd Sun 4th Load Favourites

Please note that all times are in Central European Summer Time (CEST)

Programme Filter
timer Loading ... please wait
Fri 02 10:45 - 11:30 CEST
Chairperson(s):
B. Chanana INDIA

Channel 3

10.45
B. Chanana INDIA
Management of dropped IOL and nucleus

10.51
S.J. Chen TAIWAN
Inadvertent globe perforation during local anaesthesia for cataract surgery and its Management

10.57
H. Heimann UK
Retinal detachment in mismanaged cataract surgery: Prevention, etiology, and management

11.03
K. Fong   MALAYSIA
Cystoid macular edema: When and how to treat?

11.09
M. Zinckernagel   SWITZERLAND
Endophthalmitis: early detection, differentiation from sterile reaction, and management

11.15
Discussion

11.30
End of session

 

Fri 02 11:45 - 12:30 CEST
Chairperson(s):
G. Pertile ITALY, G. Prigione ITALY

Channel 3

11.45
G. Pertile ITALY
Introduction

11.47
G. Prigione ITALY
Strategies to deal with an intraocular foreign body

11.54
G. Caputo FRANCE
Foreign bodies and perforating traumas in children

12.01
H. Mortada 
Management of late complications correlated with foreign body injuries

12.08
G. Pertile ITALY
Pitfalls in removing intraocular foreign bodies

12.15
Discussion

12.30
End of session

 

Fri 02 13:45 - 14:30 CEST
Chairperson(s):
D. E. Pelayes ARGENTINA

Channel 3

13.45
M. Batataglia Parodi ITALY
Multimodal diagnostic tools in DME

13.50
R. Cano Hidalgo MEXICO
Angio SS OCT in DME

13.55
V. Chong UK
The role of laser in DME

14.00
D. E. Pelayes argentina
New trends of pharmacotherapy in DME

14.05
F. Fayyad JORDAN
Mastering surgical management

14.10
F. March de Ribot SPAIN
Combining lines in DME and proliferative retinopathy

14.15
Discussion

14.30
End of session

 

Fri 02 14:45 - 15:30 CEST
Chairperson(s):
J. Monés SPAIN

Channel 3

14.45
J. Monés SPAIN
Introduction

14.50
G. Staurenghi ITALY
The new nomenclature for AMD

14.58
K. Csaky USA
The role of functional testing in AMD

15.06
J. Monés SPAIN
New and future treatments for AMD

15.14
Discussion

15.30
End of session

 

Fri 02 15:45 - 16:30 CEST
Chairperson(s):
O. Zeitz GERMANY

Channel 3

15.45
T. Jackson UK
Designing, executing and interpreting randomized clinical trials

15.53
L. Kodjikian FRANCE
From randomized clinical trial to real-world: efficacy of VEGF inhibitors

16.01
O. Zeitz GERMANY
Understanding safety data: From adverse events to undesirable effects

16.08
A. Joussen GERMANY
Future developments in retina: scientific, clinical and other challenges for the pipeline

16.15
Discussion

16.30
End of session

Sat 03 08:45 - 09:30 CEST
Chairperson(s):
C. Creuzot-garcher FRANCE, M. Gillies AUSTRALIA

Channel 3

08.45
C. Creuzot-Garcher FRANCE
From Clinical trial to registry: pros and cons

08.53
M. Gillies AUSTRALIA
Long term observational study, the FRB example in AMD

09.01
D. Barthelmes SWITZERLAND
Key learnings from FRB for clinical practice

09.09
V. Daien FRANCE
From registry data to nationwide study

09.17
Discussion

09.30
End of session

 

Sat 03 09:45 - 10:30 CEST
Chairperson(s):
E. Pilotto ITALY, R. Schumann THE GERMANY

Channel 3

09.45
R. Schumann GERMANY
Premacular membranes in humans: histologic evidence for different cell populations in fibrotic process

09.51
E. Pilotto ITALY
Morphofunctional evaluation in vitreomacular interface abnormalities

09.57
N. Lois UK
Vitreomacular interface abnormalities in diabetic macular oedema

10.03
R. Frisina ITALY
Surgery in idiopathic cases

10.09
M. de Smet NETHERLANDS
Can robotics contribute to the performance of vitreomacular surgery?

10.15
Discussion

10.30
End of session

 

Sat 03 10:45 - 11:30 CEST
Chairperson(s):
J. F. Korobelnik FRANCE

Channel 3

10.45
G. Staurenghi ITALY
Overview on OCTA

10.51
J. Figueira PORTUGAL
OCTA in Diabetic Retinopathy

10.57
N. Eter GERMANY
OCTA in AMD

11.03
M. B. Rougier FRANCE
OCT A and optic disc

11.09
J. F. Korobelnik FRANCE
Quantification in OCT-A: what for?

11.15
Discussion

11.30
End of session

Sat 03 13:30 - 14:15 CEST
Chairperson(s):
R. Hillier UK, R. Muni CANADA

Channel 3

13.30
R. Hillier UK
Welcome (including audience poll – ‘How many audience members currently incorporate pneumatic retinopexy into their routine clinical practice?’)

13.32
P. Kertes CANADA
Review of the Pneumatic Retinopexy Trial findings

13.34
R. Hillier UK
Top line findings of the Pneumatic Retinopexy versus Vitrectomy for the Management of Primary Rhegmatogenous Retinal Detachment Outcomes Randomized Trial (PIVOT) and post hoc analyses

13.36
R. Muni CANADA
Top line findings of the Retinal Displacement Detected with Fundus Autofluorescence Imaging following Pneumatic Retinopexy vs Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment Studies (INTEGRITY and ALIGN)

13.38
R. Hillier UK
The fundamentals of pneumatic retinopexy technique: Principles of intraocular gas

13.42
P. Kertes CANADA
The fundamentals of pneumatic retinopexy technique: Case selection

13.46
R. Muni CANADA, R. Hillier UK
The fundamentals of pneumatic retinopexy technique: Step-by-step surgical technique (‘the PIVOT method’)

13.54
E. Mavrikakis GREECE
The fundamentals of pneumatic retinopexy technique: Management of complications

13.58
R. Hillier UK, R. Muni CANADA, P. Kertes CANADA, E. Mavrikakis GREECE
Practical pearls and pitfalls when starting out: panel ‘round robin’ discussion

14.06
Discussion

14.15
End of session

Sat 03 15:30 - 16:15 CEST
Chairperson(s):
A. Fung AUSTRALIA, W. Mieler USA, F. Sarraf USA

Channel 3

15.30
V. Sadda USA
Case 1

15.34
C. Boon THE NETHERLANDS
Case 2

15.38
R. Dolz-Marco SPAIN
Case 3

15.42
R. Gallego-Pinazo SPAIN
Case 4

15.46
S. Mrejen FRANCE
Case 5

15.50
A. Tan SINGAPORE
Case 6

15.54
S. Yzer NETHERLANDS
Case 7

15.58
Discussion

16.15
End of session

Sat 03 16:30 - 17:15 CEST
Chairperson(s):
A. Koh SINGAPORE, R. Martins Da Silva PORTUGAL

Channel 3

16.30
A. Koh SINGAPORE
Introduction

16.31
A. Carneiro PORTUGAL
Clinical presentation: Epidemiology, differences between ethnic groups, genetic factors – CFH, HTRA1 vs others

16.36
M. Falcão PORTUGAL
Diagnosis and differentials: Current diagnostic criteria, Important differential diagnoses

16.41
G. Staurenghi ITALY
Diagnosis and differentials: Multimodal findings on OCT, ICGA, ICGA

16.46
S. Sadda USA
Treatment: PCV Anti-VEGF Monotherapy (PLANET/HAWK/HARRIER)

16.50
R. Silva PORTUGAL
Treatment: Treat and Extend for PCV (Atlantic study)

16.54
A. Koh SINGAPORE
Treatment: Combination therapy (Latest EVEREST data)

16.58
A. Koh SINGAPORE
Treatment: Current Treatment Algorithm based on Data

17.01
Discussion

17.14
R. Silva PORTUGAL
Closing points and summary

17.15
End of session

Sun 04 09:45 - 10:30 CEST
Chairperson(s):
G. Pertile ITALY, A. Polito ITALY

Channel 3

09.45
G. Pertile ITALY
Introduction

09.47
R. Tadayoni FRANCE
My preferred peeling strategies in myopic foveoschisis and holes: how, when and why

09.54
Discussion

09.57
E. Maggio ITALY
Anatomic and functional outcomes after surgery: what should we tell the patient?

10.04
Discussion

10.07
M. Mete   ITALY
What if the ILM is gone? Surgery for occuring, recurring or persisting holes after peeling

10.14
Discussion

10.17
C. Mateo SPAIN
Posterior retinal detachment in high myopia

10.24
Discussion

10.27
G. Pertile ITALY
Closing remarks and take home messages

10.30
End of session

 

Sun 04 10:45 - 11:30 CEST
Chairperson(s):
C. Boon THE NETHERLANDS

Channel 3

10.45
E. van Dijk THE NETHERLANDS
Pathogenesis and diagnosis of CSC

10.53
Discussion

10.55
S. Yzer THE NETHERLANDS
Differential diagnosis of CSC

11.03
Discussion

11.05
C. Boon THE NETHERLANDS
Evidence-based treatment of CSC

11.13
Discussion

11.15
Questions & Answers

11.30
End of session

Sun 04 12:45 - 13:30 CEST
Chairperson(s):
J. Garcia-Arumi SPAIN

Channel 3

12.45
B. Corcostegui SPAIN
Risc factors in Proliferative Vitreoretinopathy

12.51
E. El Rayes EGYPT
Vitreomacular interface. Epiretinal membranes management

12.57
S. Rizzo ITALY
Endotamponades in PVR

13.03
T. Wolfensberger SWITZERLAND
Retinotomy-retinectomy in PVR. When and how

13.09
J. Garcia-Arumi SPAIN
Staining and PFCL. Viscodissection in closed funnel

13.15
Discussion

13.30
End of session

 

EURETINA 2020 Virtual

Frank Holz

Prof. Frank G. Holz, FEBO, FARVO

University Eye Hospital Bonn
EURETINA President

Dear Colleagues,

We are delighted to announce EURETINA 2020 Virtual, taking place from 2-4 October, and delivering the highest quality scientific content curated by world-renowned experts in the field of retina.

The Virtual Congress will present up to 4 Channels of scientific content, to include EURETINA Sessions & Keynotes on Channel 1, International Symposia on Channel 2, Instructional Courses on Channel 3, as well as a fourth Channel running on Saturday to present the highest scoring Free Papers.

Having extensively researched the most favourable and engaging formats for this new digital landscape, session times have been reduced to 45 minutes, to present engaging, shortened presentations with live discussion throughout.

The virtual Congress will also present a virtual Exhibition, as well as virtual Networking Lounges and the usual programme of industry sponsored Satellite Symposia. We are most grateful to our loyal sponsors for their support in this new endeavour and are glad to be able to still have the opportunity to engage directly with them during the annual meeting.

We very much hope that you will join us at this year’s first virtual EURETINA Congress and encourage you to avail of the reduced registration rates until September 25th.

With very best wishes,

Prof. Frank G. Holz, FEBO, FARVO
President, EURETINA

Registration Information

Do you have a VAT number? If so, please contact registration@euretina.org for information on how to register. Please also contact us if you are a registered business located outside of the EU.

If you are an EURETINA Member or have submitted an abstract, you may already have an account.

If you do not know the login details for this account, please click on the ‘Forgot password’ link on the registration page and they will be sent to you. Alternatively, contact the Registration Department.

Prices are in Euro & listed without VAT
VAT is charged at 20%
EARLY FEE
5 Aug – 25 Sept
LATE FEE
26 Sept – 4 Oct
EURETINA Member 50 65
Non – Member 95 110
Ophthalmic Nurse / Technician* 50 65

*Documentation such as a work ID or verification letter from your hospital is required and must be uploaded during the registration process for approval.

Additional Info Categories Groups Cancellations

Keynote Lectures – EURETINA 2020 Virtual

Richard Spaide USA speakerfeature EURETINA Lecture Richard Spaide USA
Marta S. FigueroaKreissig LectureMarta S. FigueroaSPAIN
Stanislao RizzoGisbert Richard Lecture Stanislao RizzoITALY

src

Safety Review Committee (SRC) Report

Post-marketing reports have highlighted the occurrence of intraocular inflammation (IOI) in association with retinal vasculitis and retinal vascular occlusion with brolucizumab, which differs from the common experience with other approved anti-VEGF agents.

A Safety Review Committee (SRC) consisting of clinical trial, imaging, and uveitis experts as well as Data Monitoring Committee members was established by Novartis to independently review these post-marketing cases.

View Report

Sign up to EURETINA


© EURETINA All rights reserved
Loading please wait